Biomolecular Condensates: A Novel Opportunity for Drug Discovery
Recorded On: 06/03/2021
Biomolecular condensates are membraneless organelles that compartmentalize biomolecules such as proteins and nucleic acids (Banani et al. Nat Rev Mol Cell Biol 2017). In contrast to classical membrane-bound organelles, condensates are dynamic and reversible compartments that often form by liquid-liquid phase separation (LLPS). LLPS is a physicochemical process by which biomolecules demix into
two separate phases through multivalent interactions between nucleic acids, tethered multivalent protein domains, and intrinsically disordered proteins.
Biomolecular condensates regulate and compartmentalize an ever-increasing number of cellular functions includingRNA metabolism, transcription, and signal transduction, among others (Alberti et al. Cell 2019). Altering the concentration, post-translational modification, or sequence of condensate components can modulate condensates with functional consequences. Thus, biomolecular condensates have been implicated in diseasessuch as neurodegeneration, cancer, and infectious diseases (Alberti and Dormann. Ann Rev Gen 2019). We find that aberrant condensates drive many multifactorial diseases.
Focusing drug discovery efforts on condensates presents novel opportunities for therapeutic development (Wheeler. Emerg Top Life Sci 2020). In this presentation we will discuss different approaches by which condensate modulating drugs, or c-mods, that alter the composition, stability or dissolution of condensates can prevent or reverse disease. Initial results from a condensate-based screen to identify c-mods with potential therapeutic activity for amyotrophic lateral sclerosis (ALS) will be presented.
Marta Frigolé-Vivas, Ph.D.
Marta Frigolé-Vivas is a scientist at Dewpoint Therapeutics.
She has a background in medicinal chemistry and condensate biology. She is passionate about leveraging condensate biology to develop novel drugs for currently unmet medical needs.
She completed her PhD at the IRB Barcelona focussing on using small molecules to finetune
the function of intrinsically disordered proteins (IDPs), which are not amenable to structure-based drug discovery methods. Modulating the propensity of IDPs to form condensates emerged as a promising